Clinical trials for Aggressive primary cutaneous T-cell lymphoma
56 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 1NCT05544968Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic MalignanciesMedical College of Wisconsin · PI: Guru Subramanian Guru Murthy, MD, MS
- RECRUITINGPhase 1NCT07055477A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)National Cancer Institute (NCI) · PI: Samuel Y Ng, M.D.
- RECRUITINGPhase 1NCT07047885Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)H. Lee Moffitt Cancer Center and Research Institute · PI: Yumeng Zhang, MD
- RECRUITINGN/ANCT06860880Combating Cancer-Related Fatigue: A Personalized Supportive Care ProgramUNC Lineberger Comprehensive Cancer Center · PI: Christopher Jensen, MD MSCR
- RECRUITINGPHASE1, PHASE2NCT07022964CD5 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital · PI: Tengyu Wang, Ph.D
- RECRUITINGNCT07132567Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceKyowa Kirin Co., Ltd. · PI: HaeMi Park
- RECRUITINGPHASE1, PHASE2NCT06925464CD7 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGPhase 1NCT06914037A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological MalignanciesTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPhase 2NCT06854653A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCLPrescient Therapeutics, Ltd.
- RECRUITINGPhase 2NCT06698822A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIAM.D. Anderson Cancer Center · PI: Julia Dai, MD
- RECRUITINGNCT06588868Systemic Therapies in the Treatment of Cutaneous T-cell LymphomaFondazione Italiana Linfomi - ETS · PI: Pietro Quaglino, MD
- RECRUITINGPhase 3NCT06470451Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCLSoligenix
- RECRUITINGPhase 1NCT06733441A Study of TLN-254 in Participants With Relapsed or Refractory T-cell LymphomaTreeline Biosciences, Inc.
- RECRUITINGNCT07003100A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care MogamulizumabCity of Hope Medical Center · PI: Christiane Querfeld
- ENROLLING BY INVITATIONNCT06665490Pilot Study to Characterize the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of CLn® Skin Care Body WashNorthwestern University · PI: Alan Zhou
- RECRUITINGNCT06436677A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell LymphomaPeking University First Hospital · PI: YANG WANG, MD
- ACTIVE NOT RECRUITINGPhase 2NCT06485219A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell LymphomaChengdu Zenitar Biomedical Technology Co., Ltd · PI: Ting Niu, Doctor
- RECRUITINGNCT06207812Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid PapulosisM.D. Anderson Cancer Center · PI: Julia Dai, MD
- ACTIVE NOT RECRUITINGPhase 1NCT05944562Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary SyndromeWashington University School of Medicine · PI: Neha Mehta-Shah, M.D.
- RECRUITINGNCT06382844Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCLInstituto de Investigación Biomédica de Salamanca · PI: Julia M Almeida Parra, Prof.
- RECRUITINGPhase 1NCT04234048Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin LymphomaSciTech Development, Inc. · PI: Ali Moiin, MD
- RECRUITINGPhase 2NCT05956041Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell LymphomasUniversity of Michigan Rogel Cancer Center · PI: Ryan Wilcox
- RECRUITINGEarly Phase 1NCT05838599Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis FungoidesNorthwestern University · PI: Alan Zhou
- RECRUITINGPhase 2NCT05313243Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell LymphomaYale University · PI: Tarsheen Sethi, MD
- ACTIVE NOT RECRUITINGPhase 4NCT06285370A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic TherapyKyowa Kirin China Pharmaceutical Co., Ltd. · PI: Yuankai Shi
- RECRUITINGPhase 1NCT05414500Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis FungoidesUniversity of Alabama at Birmingham · PI: Amit Mehta, M.D.
- RECRUITINGNCT05157581Extracorporeal Photopheresis in Sezary SyndromeOleg E. Akilov, MD, PhD · PI: Oleg E Akilov, MD, PhD
- RECRUITINGNCT06421571The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult PatientsNational and Kapodistrian University of Athens
- RECRUITINGPhase 2NCT04930653Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell LymphomaCity of Hope Medical Center · PI: Christiane R Querfeld
- RECRUITINGPhase 2NCT05357794Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis FungoidesM.D. Anderson Cancer Center · PI: Bouthaina Dabaja, MD
- RECRUITINGN/ANCT05333367MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal PhotochemotherapyCentre Hospitalier Universitaire de Besancon
- RECRUITINGPhase 1NCT05296304A Study of Bexarotene Combined With Radiotherapy in People With Mycosis FungoidesMemorial Sloan Kettering Cancer Center · PI: Brandon Imber, MD
- ACTIVE NOT RECRUITINGPhase 1NCT03240211Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCLUniversity of Virginia · PI: Owen O'Connor, MD, PhD
- ACTIVE NOT RECRUITINGPhase 1NCT04652960Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary SyndromeNational Cancer Institute (NCI) · PI: Neha Mehta-Shah
- ACTIVE NOT RECRUITINGPhase 2NCT04960618Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary SyndromeMemorial Sloan Kettering Cancer Center · PI: Alison Moskowitz, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04745234Mogamulizumab Q4week Dosing in Participants With R/R CTCLKyowa Kirin, Inc.
- RECRUITINGN/ANCT04087629StrataCTX® as a Steroid Sparing DeviceColumbia University · PI: Larisa J. Geskin, MD
- RECRUITINGPhase 2NCT05680558Photopheresis in Early-stage Mycosis FungoidesColumbia University · PI: Larisa Geskin, MD
- RECRUITINGNCT04904146Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.Lund University Hospital
- ACTIVE NOT RECRUITINGPhase 1NCT04072458A Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesBio-Path Holdings, Inc.
- RECRUITINGPhase 2NCT04256018Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary SyndromeStanford University · PI: Youn H Kim, MD
- RECRUITINGN/ANCT04045470A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell LymphomaDana-Farber Cancer Institute · PI: Cecilia Larocca, MD
- ACTIVE NOT RECRUITINGPhase 1NCT03952078A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell LymphomaCorvus Pharmaceuticals, Inc. · PI: Suresh Mahabhashyam, MD, MPH
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03598998Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell LymphomasCity of Hope Medical Center · PI: Alex F Herrera
- RECRUITINGNCT03932279Characterization of the Microbiome in Cutaneous T Cell LymphomaNorthwestern University · PI: Alan Zhou, MD
- ACTIVE NOT RECRUITINGPhase 2NCT03385226A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)University College, London · PI: Tim Illidge
- ACTIVE NOT RECRUITINGPhase 1NCT03602157Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCLUNC Lineberger Comprehensive Cancer Center · PI: Natalie Grover, MD
- RECRUITINGPhase 2NCT03587844Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome PatientsMemorial Sloan Kettering Cancer Center · PI: Alison Moskowitz, MD
- RECRUITINGPhase 2NCT03398161Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis FungoidesM.D. Anderson Cancer Center · PI: Bouthaina S Dabaja
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03278782Study of Pembrolizumab (MK-3475) in Combination With RomidepsinM.D. Anderson Cancer Center · PI: Swaminathan P Iyer, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03011814Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell LymphomaCity of Hope Medical Center · PI: Christiane Querfeld, MD
- RECRUITINGNCT02848274ID Of Prognostic Factors In Mycosis Fungoides/Sezary SyndromeStanford University · PI: Youn H Kim, MD
- RECRUITINGNCT02702310Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis FungoidesVanderbilt-Ingram Cancer Center · PI: Austin Kirschner, MD, PhD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02503423Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and LymphomasTaiho Oncology, Inc.
- ACTIVE NOT RECRUITINGPhase 2NCT01352520SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)M.D. Anderson Cancer Center · PI: Auris O Huen, MD
- RECRUITINGNCT00177268Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis ResearchUniversity of Pittsburgh · PI: Oleg E Akilov, M.D., PhD